Company Description
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States.
Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant.
It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015.
PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Joshua N. Silverman |
Contact Details
Address: 23046 Avenida De La Carlota, Suite 600 Laguna Hills, California 92653 United States | |
| Phone | (917) 595.2850 |
| Website | pharmacyte.com |
Stock Details
| Ticker Symbol | PMCB |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001157075 |
| CUSIP Number | 71715X203 |
| ISIN Number | US71715X2036 |
| Employer ID | 62-1772151 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joshua N. Silverman | Interim Chief Executive Officer, President and Director |
| Carlos A. Trujillo CPA, CPA | Chief Financial Officer |
| Dr. Jose L. Iglesias M.D. | Consulting Chief Medical Officer |
| Dr. Hans-Peter Hammes | Member of Medical and Scientific Advisory Board and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | ARS | Filing |
| Mar 18, 2024 | 10-Q | Quarterly Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 15, 2023 | 10-Q | Quarterly Report |
| Nov 28, 2023 | 3 | Initial statement of beneficial ownership of securities |
| Nov 24, 2023 | 8-K | Current Report |
| Nov 16, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 8-K | Current Report |